Heart Failure

In a retrospective study of 132 patients with transthyretin amyloid cardiomyopathy (ATTR-CM) who switched from tafamidis to acoramidis, 49.2% had a cardiovascular-related hospital or emergency department...

A matched retrospective claims analysis found more fracture-related hospitalizations and higher costs in ATTR-CM than in heart failure (HF) and non-HF control patients.

The HF Stats 2026 report examines US heart failure trends, highlighting rising mortality, younger patients, and gaps in treatment.

HFSA 2026 will spotlight late-breaking trials in heart failure drugs, amyloidosis imaging, cardiomyopathy, and device-based care.

In a post hoc analysis of the phase 3 HELIOS-B trial, vutrisiran reduced worsening of left atrial strain at 30 months among patients with transthyretin amyloidosis with cardiomyopathy.

Experts discuss how the 2025 ACC/AHA blood pressure guidelines may affect hypertension treatment decisions.

A meta-analysis of randomized controlled trials presented at the American College of Cardiology’s Annual Scientific Session suggests RNA therapeutics reduce mortality and cardiac failure risk in...

In a landmark survival analysis of 596 consecutive patients with transthyretin amyloid cardiomyopathy, worsening NT-proBNP and heart failure hospitalization at 6 months were independently associated with...

In this expert interview, Deepak L. Bhatt, MD, MPH discusses guideline-based and emerging strategies for reducing recurrent ischemic stroke risk. From dietary interventions and blood pressure control to...

In SOUL, oral semaglutide was associated with fewer composite heart failure events in patients with type 2 diabetes and baseline heart failure.